Roskamp Institute Release: Key Clinical Trial of Alzheimer’s Disease Drug Begins in Europe
2/14/2012 8:57:18 AM
SARASOTA, Fla.--(BUSINESS WIRE)--A research team today announced the launch of a European large-scale clinical trial of Nilvadipine, an Alzheimer’s disease drug developed at the Roskamp Institute (www.rfdn.org) in Sarasota. More than 500 Alzheimer’s patients in nine European countries will participate in the phase III trial designed to study the effectiveness of the medication.
comments powered by